The following article is part of conference coverage from the 2019 American Psychiatric Association Annual Meeting (APA 2019) in San Francisco, CA. Psychiatry Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in psychiatry. Check back for the latest news from APA 2019.
SAN FRANCISCO — Leveraging pharmacogenetics for selecting treatments may benefit patients with treatment-resistant schizophrenia and other psychotic disorders, according to a retrospective chart review presented at the American Psychiatric Association Annual Meeting, held May 18-22, 2019, in San Francisco, California.
Researchers compared outcomes in individuals admitted to inpatient psychiatric units who were given genetic testing with those who were not. Pharmacogenetics can be used to improve treatment adherence which may be affected by drug side effects. The participants’ clinical features were reviewed, as were their metabolic parameters, choice of medications, length of stay, care after hospitalization, and rate of readmission. Study outcomes included clinician adherence to recommendations for pharmacogenetics testing, patient compliance to the recommended treatment, and rate of readmission, indicative of treatment success.
“While there is a literature that supports the patient’s clinical improvement, time, and cost saving benefit when choosing an antipsychotic based on the patient’s pharmacogenetics, the studies are limited,” noted the investigators.
For more coverage of APA 2019, click here.
Carvajal MT, Odom CR, Padilla FOPM, et al. A retrospective analysis of genetic testing in patients with treatment-resistant schizophrenia and other psychotic disorders at BCHS inpatient unit. Poster presentation at: American Psychiatric Association Annual Meeting; May 18-22, 2019; San Francisco, CA. Abstract 25.